Orchid Pharma has uploaded the audio recording of its quarterly earnings call, which was held on August 21, 2026. The session discussed the company's unaudited limited reviewed financial results for the first quarter of FY27, ended June 30, 2026.

The call took place at 3:00 pm IST and was hosted by Systematix Institutional Equities. Management provided insights into operational and financial performance for the period.

Management Participation

Key executives represented Orchid Pharma during the session:

• Manish Dhanuka, Managing Director
• Mridul Dhanuka, Whole Time Director
• Sunil Kumar Gupta, Chief Financial Officer

Regulatory Disclosure

The intimation was issued pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. It references SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Kapil Dayya, Company Secretary and Compliance Officer, signed the disclosure. The information is available on the company's website at www.orchidpharma.com .

Audio Recording Access

Investors and analysts can access the audio recording via the link provided on the company's website. The call was conducted as an audio conference; no video recording is available.

Dial-In Details

For reference, the dial-in numbers used during the call are listed below:

Orchid Pharma Limited has scheduled a Board meeting for August 01, 2026, to approve the allotment of fully paid-up equity shares to eligible shareholders of Dhanuka Laboratories Limited. This procedural step advances the Scheme of Amalgamation, allowing Orchid Pharma to finalize the share exchange mechanism with Dhanuka Laboratories shareholders based on their holdings as of the July 23, 2026 record date.

The company notified the National Stock Exchange of India Limited and BSE Limited on July 28, 2026, in compliance with Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation serves as a continuation of earlier disclosures made on July 10, 2026, regarding the upcoming Board proceedings.

Key Meeting Details

The Board of Directors will convene on Saturday, August 01, 2026. The primary agenda item involves the formal approval for issuing equity shares with a face value of ₹10 each. These shares are designated for distribution to Dhanuka Laboratories Limited shareholders who were recorded in the register on July 23, 2026.

Amalgamation Context

The share allotment is executed pursuant to the Scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited. Under this structure, Dhanuka Laboratories is identified as the "Amalgamating Company," while Orchid Pharma serves as the "Amalgamated Company." The issuance of new equity shares represents the consideration paid to Dhanuka shareholders for their stake in the merging entity.

What the Numbers Show

The fixed face value of ₹10 per equity share establishes the nominal basis for the capital expansion required to accommodate Dhanuka Laboratories shareholders. While the total number of shares to be allotted depends on the conversion ratio defined in the Scheme and the number of eligible shareholders as of July 23, 2026, the immediate impact is an increase in Orchid Pharma’s issued share capital. This dilution is structural rather than operational, reflecting the consolidation of two corporate entities into a single reporting framework under Orchid Pharma’s leadership.